A
SYRE icon

AlphaQuest’s Spyre Therapeutics SYRE Stock Holding History

AlphaQuest’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,538
Closed -$116K – 1845
2025
Q4 		$116K Sell
3,538
-62,625
-95% -$1.64M 0.01% 1687
2025
Q3 		$1.11M Buy
66,163
+61,989
+1,485% +$1.01M 0.07% 389
2025
Q2 		$62.5K Buy
4,174
+983
+31% +$14.5K 0.01% 1571
2025
Q1 		$51.5K Buy
3,191
+993
+45% +$20.7K 0.01% 1520
2024
Q4 		$51.2K Sell
2,198
-3,456
-61% -$101K 0.01% 1287
2024
Q3 		$166K Buy
5,654
+4,131
+271% +$115K 0.01% 1133
2024
Q2 		$35.8K Buy
+1,523
New +$51.4K ﹤0.01% 1189

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

AlphaQuest's SYRE Position: Q1 2026 in Review

AlphaQuest sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 3,538 shares — an estimated $116K sold.

AlphaQuest first reported a position in SYRE in Q2 2024 and held it in 7 quarters. The position peaked at $1.11M in Q3 2025. 198 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • AlphaQuest reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 3,538 Spyre Therapeutics shares in Q1 2026, an estimated $116K.
  • AlphaQuest first reported a position in Spyre Therapeutics in Q2 2024 and held it in 7 quarters.
  • AlphaQuest's Spyre Therapeutics position peaked at $1.11M in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.